Search

Your search keyword '"Brahmania, Mayur"' showing total 355 results

Search Constraints

Start Over You searched for: Author "Brahmania, Mayur" Remove constraint Author: "Brahmania, Mayur"
355 results on '"Brahmania, Mayur"'

Search Results

1. Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease.

2. SAT-129 Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma

5. Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes

6. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

8. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

9. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas

10. OP-5 ALCOHOL-ASSOCIATED HEPATITIS IN LATIN AMERICA: RESULTS FROM THE AH-LATIN STUDY

12. SAT-285-YI Incorporation of cholestasis into prognostic models improves predictive outcome in alcohol-related liver disease: a retrospective multicenter study

13. SAT-280 Emergence of co-morbidities in alcohol-related hepatitis over time: insights from the WALDO cohort

16. Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.

18. Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021.

22. Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection

29. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

30. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

36. O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS

37. O-13 SUB-OPTIMAL GLOBAL PUBLIC HEALTH POLICIES AND STRATEGIES TO TACKLE HEPATOCELLULAR CARCINOMA

38. O-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA

39. Safety of Combination Biologic and Antirejection Therapy Post–Liver Transplantation in Patients With Inflammatory Bowel Disease

41. Strategies to eliminate hepatitis C virus infection in the Americas

42. Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma

44. Diabetes increases risk of mortality in alcohol-related liver disease

49. O-21 EVIDENCE OF SUBOPTIMAL PUBLIC HEALTH POLICIES ON HEPATOCELLULAR CARCINOMA IN THE AMERICAS: A HUGE DEBT OF OUR REGION

50. Reducing length of stay in patients following liver transplantation using the model for continuous improvement

Catalog

Books, media, physical & digital resources